Amarin Corporation PLC (AMRN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amarin Corporation PLC stock (AMRN) is currently trading at $14.47. Amarin Corporation PLC PS ratio (Price-to-Sales) is 1.41. Analyst consensus price target for AMRN is $12.00. WallStSmart rates AMRN as Sell.
- AMRN PE ratio analysis and historical PE chart
- AMRN PS ratio (Price-to-Sales) history and trend
- AMRN intrinsic value — DCF, Graham Number, EPV models
- AMRN stock price prediction 2025 2026 2027 2028 2029 2030
- AMRN fair value vs current price
- AMRN insider transactions and insider buying
- Is AMRN undervalued or overvalued?
- Amarin Corporation PLC financial analysis — revenue, earnings, cash flow
- AMRN Piotroski F-Score and Altman Z-Score
- AMRN analyst price target and Smart Rating
Amarin Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Amarin Corporation PLC (AMRN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Amarin Corporation PLC (AMRN) Key Strengths (3)
Growing significantly faster than its price suggests
Trading below book value, meaning the market prices it less than net assets
Paying $1.41 for every $1 of annual revenue
Supporting Valuation Data
Amarin Corporation PLC (AMRN) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -21.00%, a shrinking business
Earnings declining -94.20%, profits shrinking
Company is losing money with a negative profit margin
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Amarin Corporation PLC (AMRN) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.3/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Book, Price/Sales. Valuation metrics including PEG Ratio (0.81), Price/Sales (1.41), Price/Book (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -21.00%, EPS Growth at -94.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -8.21%, Operating Margin at -4.59%, Profit Margin at -18.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -8.21% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -21.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AMRN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AMRN's Price-to-Sales ratio of 1.41x trades at a deep discount to its historical average of 18.17x (34th percentile). The current valuation is 99% below its historical high of 143.89x set in Feb 2006, and 370% above its historical low of 0.3x in Jul 2018.
Compare AMRN with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Amarin Corporation PLC (AMRN) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Amarin Corporation PLC is in a turnaround phase, with management focused on restoring profitability. Revenue reached 214M with 21% decline year-over-year. The company is currently unprofitable, posting a -18.2% profit margin.
Key Findings
Generating 15M in free cash flow and 15M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 123M in cash.
Revenue contracted 21% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -18.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Amarin Corporation PLC.
Bottom Line
Amarin Corporation PLC is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(46 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:21:27 AM
About Amarin Corporation PLC(AMRN)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.